Advertisement
Advertisement

EWTX

EWTX logo

Edgewise Therapeutics, Inc. Common Stock

32.70
USD
Sponsored
+0.01
+0.03%
May 22, 16:00 UTC -4
Closed
exchange

After-Market

32.67

-0.03
-0.08%

EWTX Earnings Reports

Positive Surprise Ratio

EWTX beat 14 of 21 last estimates.

67%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.50
Implied change from Q1 26 (Revenue/ EPS)
--
/
+8.70%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+47.06%

Edgewise Therapeutics, Inc. Common Stock earnings per share and revenue

On May 07, 2026, EWTX reported earnings of -0.46 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 7.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.81% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.50 USD, with revenue projected to reach -- USD, implying an increase of 8.70% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
logo
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
logo
Gossamer Bio, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.20
Surprise
-18.62%
logo
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-
Actual
-$4.76
Surprise
-
logo
Sensei Biotherapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.63
Actual
-$28.79
Surprise
-4452.50%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
logo
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
logo
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
logo
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
logo
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
For Q1 2026, Edgewise Therapeutics, Inc. Common Stock reported EPS of -$0.46, beating estimates by 7.33%, and revenue of $0.00, 0% as expectations.
The stock price moved down -3.81%, changed from $36.99 before the earnings release to $35.58 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 9 analysts, Edgewise Therapeutics, Inc. Common Stock is expected to report EPS of -$0.50 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement